Lorlatinib/lorlatinib (Borina) belongs to the first generation of targeted drugs

Lorlatinib/Lorlatinib (Lorlatinib) belongs to the third generation of ALK inhibitors. ALK inhibitors are generally divided into three generations according to the order of development and therapeutic effect. The first-generation ALK inhibitors, such as crizotinib, are the earliest targeted drugs used to treat ALK-positive non-small cell lung cancer and can effectively inhibit tumor growth caused by ALK gene rearrangements. However, as treatment progresses, many patients develop drug resistance, leading to tumor progression.

Second generationALK inhibitors, such as alectinib and brigatinib, have better effects in treating drug-resistant lung cancer. They can effectively combat the problem of tumor progression that occurs after resistance to first-generation drugs, and also show good efficacy in the treatment of brain metastases.

Lorlatinib, as a third-generation ALK inhibitor, further optimizes the therapeutic effect of ALK-positive non-small cell lung cancer. Compared with the previous two generations of drugs, lorlatinib has stronger blood-brain barrier penetration ability and can effectively treat brain metastases in patients with ALK-positive lung cancer. It is also effective in patients who are resistant to other ALK inhibitors and can inhibit resistance caused by genetic mutations. Therefore, lorlatinib is considered an "upgraded" drug for the treatment of ALK-positive non-small cell lung cancer and is suitable for early treatment and drug-resistant patients.

In general, as a third-generation ALK inhibitorlorlatinib occupies an important position in the treatment of ALK-positive non-small cell lung cancer due to its strong efficacy and ability to treat brain metastasis, especially for those patients with brain metastasis or resistance to other ALK inhibitors. It has significant efficacy. With the deepening of follow-up research, the application scope of lorlatinib may be further expanded, bringing hope of treatment to more patients.

References:https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf